Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
about
Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticalsState-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PETPrognostic value of 18F-FDG-PET/CT in patients with nasopharyngeal carcinoma: a systematic review and meta-analysisCorrelation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy.18F-FDG PET as novel imaging biomarker for disease progression after ablation therapy in colorectal liver metastases.Association between Volumetric Analysis of Lung Metastases on F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography and Short-term Progression after I-131 Therapy for Differentiated Thyroid Carcinoma.Diagnostic value of 18F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis.18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic ResponseCross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancerPrognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancerNerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue SarcomaPredictive Role of the Number of 18F-FDG-Positive Lymph Nodes Detected by PET/CT for Pre-Treatment Evaluation of Locally Advanced Gastric Cancer.Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.Volume-Based F-18 FDG PET/CT Imaging Markers Provide Supplemental Prognostic Information to Histologic Grading in Patients With High-Grade Bone or Soft Tissue Sarcoma.The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patientsPreoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.Prediction of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Using Pretherapeutic [18F]2-Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography/Computed Tomography.The Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma.Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer.Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in patients with stage III gastric cancer.Metabolic Tumor Volume by 18F-FDG PET/CT Can Predict the Clinical Outcome of Primary Malignant Spine/Spinal Tumors.Prognostic value of positron emission tomography/computed tomography for adjuvant chemotherapy of colon cancer.PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis.Assessment of Aggressiveness of Breast Cancer Using Simultaneous 18F-FDG-PET and DCE-MRI: Preliminary Observation.Energy sources identify metabolic phenotypes in pancreatic cancer.Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.Biomarkers in pancreatic ductal adenocarcinoma.Intratumoral heterogeneity of (18)F-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma.Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.Correlation Between Infection Status of Epstein-Barr Virus and 18F-Fluorodeoxyglucose Uptake in Patients with Advanced Gastric Cancer.Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis.Acinar cell carcinoma of the pancreas presenting as diffuse pancreatic enlargement: Two case reports and literature reviewInvestigation of Association Between Borderline Pancreatic Head Cancer and Glucose Uptake by Using Positron-Emission Tomographic Studies.The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.Clinical Significance of Pretreatment FDG PET/CT in MIBG-Avid Pediatric Neuroblastoma.Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma.
P2860
Q26766690-C6FCAFEF-C777-40DD-814E-EB2264B4C8CCQ27694674-3185AD4F-EA86-4419-9248-BD6A6E425BF5Q28077401-EFF24C2F-B9EC-4180-84B4-D18672C10D64Q33676692-B923D70F-AB1A-4B8C-8C8F-EFA9E54D6284Q33695043-9CFD4531-D87E-4292-ACDB-2AA28594D802Q33827725-A94E7342-466A-4700-89F3-217F616E207FQ33833615-3F0BAB14-0A99-4755-B3C0-6E7CDD3B87E3Q33904549-C7B68088-6DB2-4F89-9915-1021C75BA90BQ35169358-74F08F24-3342-4B13-89FE-936C1933B541Q35625394-4167201F-FA16-4025-9F8D-E8A52694CE3FQ35857307-025153CB-815F-4447-924C-AE4AD8ED03FDQ36196581-7E71FC49-E37B-402A-AEEA-FEAB8ED0CF20Q36218208-D06486E5-DAD8-43C5-A440-DD4FCB2131E7Q36290046-339F65E2-BFA1-413D-8B3C-1649378D30E8Q36421044-D964BB43-C21E-4829-85A7-B1E9ACCF0924Q36570306-C17A5DD9-2302-46D5-8A04-78B5D4A7C43FQ36663805-782FDC2D-41BC-47E4-9D32-5E4DBFE10FC1Q36993625-15786D52-8604-40D1-B9FE-E3145EC0F17AQ37026232-1688A80D-699C-4FBF-AC65-11E4552DA2A6Q37097507-2B050B92-4BB4-4C8D-A14A-777B131C15B3Q37206394-2DE9A40B-A2A4-45C2-BD84-BF4CF33B5431Q37665536-4D3C382D-8BDF-4539-A894-161C1068E859Q38602774-3E51B89E-B647-461F-8E9B-565E8D0D6736Q38689156-6FA283A5-C6D0-46A5-9D37-FF9E7F8BF866Q38780923-564FD873-FC50-4B96-87F1-77D54D78854EQ38866273-B33C7155-ED7C-4E0B-8054-34EC129AE9F0Q38959840-5AE68307-ABA1-4041-B8CC-27C3A40E5D5CQ39127172-A7F0499E-B99E-4C7C-B9A9-240ED07E7514Q39375110-B0EABC13-A659-4418-BD42-0DA70647287FQ40000698-C80218A9-9695-4F16-AFE2-73041CD106FFQ40128040-F0104B61-60A8-455D-B62A-BCCEA6924F71Q40144662-798501F3-EB88-4A28-9343-B8BE81042A71Q40872263-6091E664-2583-4CBD-8503-E8A2E4ABF149Q41507039-6686C3F3-7F95-4146-A12D-10DCF97C8DDCQ41521598-5E40A42E-D73C-4E60-91F8-7C6940AFCCF5Q42365417-CE48FDEB-60F8-4DC5-9717-8E67FF7238F0Q42637699-6FC5FD71-49A4-4DBF-B271-5ED386709383Q46876969-E231D75C-9DC3-47C7-952D-78F8F47B89E9Q47360425-E90A6637-FBBE-4731-8FE8-4221B637D342Q47850078-1056BD9A-4632-4378-B195-C89BF8E8ABB4
P2860
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Prognostic Value of Metabolic ...... tients with Pancreatic Cancer.
@en
Prognostic Value of Metabolic ...... tients with Pancreatic Cancer.
@nl
type
label
Prognostic Value of Metabolic ...... tients with Pancreatic Cancer.
@en
Prognostic Value of Metabolic ...... tients with Pancreatic Cancer.
@nl
prefLabel
Prognostic Value of Metabolic ...... tients with Pancreatic Cancer.
@en
Prognostic Value of Metabolic ...... tients with Pancreatic Cancer.
@nl
P2093
P50
P1476
Prognostic Value of Metabolic ...... atients with Pancreatic Cancer
@en
P2093
Jae-Hoon Lee
Jeong Won Lee
Jong Doo Lee
Woo Jung Lee
P304
P356
10.2967/JNUMED.113.131847
P407
P577
2014-04-07T00:00:00Z